DDrare: Database of Drug Development for Rare Diseases

97. 潰瘍性大腸炎
［臨床試験数：2,269，薬物数：1,331（DrugBank：241），標的遺伝子数：114，標的パスウェイ数：181］

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (-)-3-(4-Aminophenyl)-2-methoxypropionic acid; (R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid; (S)-(-)-3-(4-Aminophenyl)-2-methoxypropionic Acid; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxyben; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride; -aminosalicylic acid; 0.25 mg RPC1063; 0.25mg RPC103; 0.25mg RPC1063; 0.5 mg RPC1063; 1 mg RPC1063; 1.0 mg RPC103; 1.0 mg RPC1063; 1.Remicade; 10 mg Natura-alpha capsule; 100; 100 mg; 150 mg; 1500mg mesalazine pellets; 15N2-tofacitinib; 2 x 10 mg Natura-alpha capsules; 2'-Fucosyllactose; 2-Hydroxybenzoic acid; 20 mg; 225mg SHP647 (PF-00547659); 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM); 25 mg Ontamalimab; 250mg mesalazine pellets; 2L polyethylene glycol/ascorbic acid; 3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III); 331731-18-1; 40 mg MSB11022; 42942019; 450 mg; 5 ASA, enemas, suppositories, corticosteroids; 5-ASA; 5-ASA (5-Aminosalicylate); 5-ASA MMx; 5-AminoSalicylic Acid; 5-Aminosalicyclic acid; 5-Aminosalicylic Acid; 5-Aminosalicylic acid; 5-Aminosalicylic acid (5-ASA); 5-Aminosalicylic acid(5-ASA) and/or Prednisone; 5-HTP; 5-amino salicylic acid; 5-amino salicylic acid (5-ASA); 5-amino-2-hydroxybenzoic acid; 5-aminosalicylate (Pentasa, Ferring); 5-aminosalicylic acid; 5-aminosalicylic acid (5-ASA); 50 mg; 500mg mesalazine pellets; 549-0261/F02-01; 6 mercaptopurine; 6-MP; 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid; 6-mercaptopurine; 75 mg Ontamalimab; 750mg mesalazine pellets; 75mg SHP647 (PF-00547659); 90 mg hydrocortisone acetate suppository with Sephure suppository applicator; A multistrain probiotic product (DSF); A07DA03; A: 1 dosis; AB (antibiotics); ABBV-006; ABBV-066; ABBV-323; ABBV-323 Dose A; ABBV-323 Dose B; ABI-M201; ABT-494; ABT-Humira; ABX464; ABX464 100mg; ABX464 25mg; ABX464 50mg; ADALIMUMAB; AEB071; AEB071A; AG011; AG011 - Capsules; AG011 - Enema; AJG501; AJG511; AJM300; ALLOPURINOL; ALTH12-1:4; ALTH12-2:4; AMG 181; AMG181; AMGEVITA; AMGEVITA (Adalimumab biosimilar ); AMGEVITA®; AMT; AMT-101; AMT-101 (oral); AND (Andrographolide); ANDROGRAPHIS PANICULATA; ANDROGRAPHIS PANICULATA (ethanol extract); AODG (Apigenin-7-O-glucuronide); APD334; APREMILAST; APRISO 375 mg extended-release capsules; APVO210; AR401959 L-arginine; AS; AS INN; ASA; ASACOL; ASC; ASP015K; ASP3291; AST-120; ATL-2502; AVONEX; AVX 470; AZA; AZAFOR 50mg; AZATHIOPRINE; AZATIOPRINA; AbGn-168H; Abalimumab; Abatacept; Abatacept (ABA); Abrilumab; Accelerated 1 hour-infusion; Accelerated 30 minutes-infusion; Acetate; Acetic acid; Acidophilus; Active group; Adalimumab; Adipate; Adipose derived, autologous mesenchymal stem cells; Adipose tissue-derived mesenchymal stem cells; Adipose-cord mesenchymal stromal cells (A-MSCs); Air; Aldesleukin; Alicaforsen; Alkaline Phosphatase; Allogeneic adipose tissue-derived mesenchymal stem cells; Allopurinol; AloASC; Aloe; Aloe Barbadensis Miller; Amg 181; Amgevita; Amgevita 40 mg Injektionslösung im Fertigpen; Amgevita 40 mg Injektionslösung in einer Fertigspritze; Amgevita 40Mg Solution for Injection; Aminosalicylic acid; Amitriptyline; Amitriptyline hydrochloride; Amoxicillin; Amoxicillin and tetracycline; Amoxicillin, metronidazole and tetracycline; Anakinra; Andecaliximab; AndoSan; Andrographolide; Anrukinzumab; Anti Beta7; Anti CD3 monoclonal antibody; Anti TNF therapy including infliximab; Anti-CD3; Anti-CD3 monoclonal antibody; Anti-IP-10 Antibody; Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human; Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody; Anti-MAdCAM antibody; Anti-TL1A; Anti-TNF Drug; Anti-TNF Therapy; Anti-TNF discontinuation: Physiological saline solution; Anti-TNF: Infliximab (Infusion); Anti-TNF:Adalimumab (Subcutaneus); Antibiotic cocktail; Apigenin; Apixaban; Apixaban 2.5 milligram; Apremilast; Apriso 0.375G ER CAP; Aquamin®; Arginine; Asacol; Asacol (mesalamine); Asacol (mesalamine) Delayed-release Tablets; Asacol 400 mg; Asacol 400 mg (mesalamine); Asacol 400 mg tablet; Asacol 400mg tablet; Asacol 800 mg (mesalamine); Asacol 800 mg tablet; Asacol 800mg tablet; Asacol Delayed Release Tablets; Asacol Delayed-Release Tablets; Asacol tablet; Asacol®; Asacol® 400 mg; Ascorbic Acid; Ascorbic acid; Aspergillus oryzae; Avonex; Azathioprine; Azathioprine (AZA); Azathioprine (AZA) or 6-mercaptopurine (6-MP); Azathioprine (Imuran) 50 mg Overencapsulated Tablet; Azathioprine and Allopurinol; Azathioprine or 6-mercaptopurine; Azatioprina; B2-ASmedic; B: 2 dosis; BBT-401-1S; BBT-401-1S, Multiple doses; BBT-401-1S, Single dose; BECLOMETASONE DIPROPIONATE; BG9418 (Interferon beta-1a); BG9924; BI 655130; BIAP; BITTER CANDYTUFT FRESH PLANT EXTRACT; BL-7040; BMS-188667; BMS-936557; BMS-986165; BMS-986165 Dose 1; BMS-986165 Dose 2; BMS-986166; BMS-986184; BMS986165; BRAZIKUMAB; BT-11; BT-11 (1000 mg); BT-11 (500 mg); BT-11 1000mg; BT-11 500 mg; BT-11 Active; BUDESONIDE; Bacteriotherapy; Balsalazide; Balsalazide Disodium; Balsalazide disodium; Baminercept; Band; Bascial prescription plus or minus herbs depend on symptoms; Basiliximab; Beclometasone; Beclometasone dipropionate; Beclomethasone dipropionate; Beclomethasone diproprionate; Behavioral: AbbVie Care 2.0; Behavioral: Administration of probiotic (L. rhamnosus and L. acidophilus); Behavioral: Increased dietary intake of salmon or cod; Behavioral: TIP / IMPACT Plus Care Coordination; Berberine; Berberine Chloride; Bertilimumab; Beta-1,3/1,6-D-Glucan; Bezlotoxumab; Bifidobacterium breve; Bifidobacterium infantis; Bifidobacterium infantis 35624; Bimekizumab; Bio-enhanced Curcumin Soft Gelatin Capsule; Biologically active human fecal microbiota; Biopsies; Biosimilar; Biosimilar infliximab; Bitterschleifenblume-ganzpflanze 1,5ml/10ml; Blood sample; Blood samples; Boulardii; Bovine intestinal alkaline phosphatase (BIAP); Bovine-Calf Alkaline Phosphatase (BIAP); Bovine-Calf Alkaline Phosphatase BIAP; Brazikumab; Broccoli; Budenofalk 2mg rectal foam; Budenofalk 3mg; Budenofalk rectal foam; Budenofalk® suppositories; Budenofalk® suppositories (BUS); Budesonide; Budesonide (6 mg); Budesonide (9 mg); Budesonide 6 mg capsules, hard (BUX-PVII prototype); Budesonide 6 mg prolonged-release capsule, hard (BUX-PVII prototype); Budesonide 6 mg prolonged-release capsules, hard (BUX-PVII prototype); Budesonide 9 mg capsules, hard (BUX-PV); Budesonide 9 mg capsules, hard (BUX-PVII prototype); Budesonide 9 mg prolonged-release capsule, hard (BUX-PVII prototype); Budesonide 9 mg prolonged-release capsules, hard (BUX-PVII prototype); Budesonide MMX; Budesonide MMX 6 mg Tablet; Budesonide MMX®; Budesonide MMX® 6 mg; Budesonide MMX® 9 mg; Budesonide-MMX; Budesonide-MMX®; Budesonide-MMX® 6 mg; Budesonide-MMX® 9 mg; Budesonide-MMX™; Butanoic acid; Butyrate; By demand; CANNABIDIOL; CARVI EXTRACTUM FLUIDUM; CAT-354; CB-01-02; CB-01-05-MMX; CC; CC-10004; CD; CGMP protein; CICLOSPORIN; CLA; CLA (Chlorogenic acid); CLIPPER*30CPR 5MG R.M.; CNTO 148; CNTO-148; CNTO1275; CNTO148; CNTO1959; CNTO312; COFFEE COAL; COLAL PRED; COLAL-PRED; COLAL-PRED®; CP; CP- 690 550; CP-690,500 5 mg; CP-690,550; CP-690,550 10 mg; CP-690,550-10; CP690,550; CS (corticosteroids) Only; CT-P13; CT-P13 SC (Infliximab); CYCLOSPORIN; CYCLOSPORINE VS INFLIXIMAB; Caffeine; Caffeine 100 mg; Calcitonin nasal spray (salmon); Calcium; Caltrate Pill; Cannabidiol; Cannabis; Cannabis, Medical; Carbon; Carbon dioxide; Carnitine; Carrageenan; Casein; Casein glycomacropeptide (CGMP); Catridecacog; Ceftriaxone; Cefuroxime; Certolizumab pegol; Chloride; Chlorogenic Acid; Cholecalciferol; Ciclosporin; Ciclosporina; Cimzia; Ciprofloxacin; Clarithromycin; Clipper; Clipper 30 cpr 5mg R.M.; Clotrimazole; Coamoxiclav; Cobitolimod; Coffee; Colal-Pred; Colazide; Coltect; Combination Oral Budesonide and Rectal Hydrocortisone; Combination Product: Beclomethasone dipropionate in addition to MC-EVOO; Combination Product: Beclomethasone dipropionate in addition to refined oil; Combination Product: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator; Corticosteroid; Corticosteroids; Corticosteroids only; CortimentMMX 9 mg; CosmoFer; CosmoFer 50mg/ml solution for infusion or injection; Cotrimoxazole; Curcumin; CyCol; CyCol™; Cyclosporin; Cyclosporine; Cyclosporine (USAN); Cytochrome P450 (CYP) Substrates; D-Proline; DACORTIN; DAND (14-Deoxyandrographolide); DDAND (14-deoxy-11,12-didehydroandrographolide); DELTACORTENE FORTE*10CPR 25MG; DELTACORTENE*20CPR 5MG; DEXTRAN 1 FOR INJECTION; DIMS0150; DIMs0150; Daclizumab; Dacortin; Decortin H; Decortin H 1 mg; Decortin H 10mg; Decortin H 20mg; Decortin H 50 mg; Decortin H 5mg; Dekavil; Dekristol; Delayed and extended release mesalazine; Deligoparin; Delmitide acetate; Deltacortene; Deltacortene 10 cpr 25mg; Deltacortene 20 cpr 5mg; Dersalazina sodica; Dersalazine; Dersalazine sodium; Device: The Colonic Transendoscopic enteral Tubing.; Dexamethasone; Dexamethasone 21-phosphate; Dextran; Dextromethorphan; Dextromethorphan 30 mg; Diagnostic Test: Antibodies to golimumab; Diagnostic Test: Calprotectin; Diagnostic Test: Colonoscopy; Diagnostic Test: Golimumab trough levels; Diagnostic Test: Histology; Diagnostic Test: Rectosigmoidoscopy; Diagnostic Test: parasitological diagnostics (coproscopy); Diagnostic Test: serum leucine-rich alpha-2 glycoprotein (LRG) levels; Diet; Doxycycline; Dukoral; E. coli Nissle; E6007; EGF enema; EMEA/H/C/000240; EMEA/H/C/000481; EN; ENTOCORT CR; ENTYVIO; ETROLIZUMAB; Ecologic 825; Eicosapentaenoic Acid; Eicosapentaenoic acid; Encapsulated Mesalamine Granules (eMG); Encapsulated faecal microbiota; Encapsulated faecal microbiota filtrate; Entecavir; Entocort EC® 3 mg; Entocort® CR; Entyvio; Entyvio 300 mg; Entyvio 300mg; Epaxal Berna (virosomal hepatitis A vaccine); Epidermal growth factor; Epidermal growth factor enema; Ergocalciferol; Ethanol; Etrasimod; Etrasimod L-arginine; Etrolizumab; Etrozulimab; Exposure to golimumab; F8IL10; FE 999301; FILGOTINIB; FITC-ADALIMUMAB; FITC-Adalimumab; FMT; FMT enema; FMT infusions; FMT oral; FP-110; FP-CYA-050; FP-CYA-053; Factor XIII; Faecal Microbiota Transplant; Faecal Microbiota Transplantation; Faecal matter; Fecal Microbial Transplant; Fecal Microbial Transplantation; Fecal Microbiota; Fecal Microbiota Enema; Fecal Microbiota Transplant; Fecal Microbiota Transplant (FMT); Fecal Microbiota Transplantation; Fecal Microbiota Transplantation (FMT); Fecal Microbiota Transplantation (FMT), OpenBiome; Fecal microbiota; Fecal microbiota capsule; Fecal microbiota transplantation; Ferric carboxymaltose; Ferrous sulphate; Filgotinib; Film-coated tablet; Flagyl; Flaxseed; Flaxseed lignan-enriched complex (FLC); Flixabi; Fluorescein; Flupentixol; Fosfomycin; Freeze-dried black raspberry powder; G321605; GB004; GED-0301; GED-0507-34-LEVO; GED-0507-34-Levo; GED-0507-34-Levo 160 mg; GED-0507-34-Levo 80 mg; GED0507; GI-270384; GLPG0974; GLPG1205; GLPG3970; GLYCYRRHIZA GLABRA ROOT; GOLIMUMAB; GS-4875; GS-5745; GS-5745 IV; GS-5745 SC; GS-6034; GSK1399686; GSK1605786; GSK1605786A; GSK2586184 400mg; GSK2831781; GSK2831781 IV infusion; GSK2831781 SC injection; GSK2982772; GSK2982772A, where A denotes the free base; GUSELKUMAB; GWP42003; Ganciclovir; Gastro-resistant phosphatidylcholine granules; Gelatin; Genetic: TPMT genotyping; Gliolan; Glutamine; Glycyrrhiza; Glycyrrhiza glabra; Gold; Golimumab; Golimumab (GLM); Golimumab (Optimization); Golimumab 1 mg per kg; Golimumab 100 mg; Golimumab 2 mg per kg; Golimumab 200 mg; Golimumab 4 mg per kg; Golimumab 400 mg; Golimumab 50 mg; Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg; Golimumab Dose 1; Golimumab Dose 2; Golimumab Liquid in Vial; Golimumab Liquid in prefilled syringe; Golimumab Prefilled Syringe; Golimumab treatment optimization.; Gralise; Granulated mesalamine; Grapefruit; Group 1- Control Diet; Group 2- UCD Diet; Guaiazulene; Guselkum; Guselkumab; Guselkumab Dose 1; Guselkumab Dose 2; H02AB; HE3286; HF2; HGS1025; HMPL-004; HMPL-004 1800 mg/day; HMPL-004 2400 mg/day; HMPL-004 high dose; HMPL-004 low dose; HMPL004-6599; HUMIRA; HUMIRA 40Mg Solution for Injection; HUMIRA ®; HYDROCORTISONE ACETATE; Hemay007; Hepatitis A Vaccine; Herbal treatment (SA100); Hextend; Hgd40; High Dose Budesonide; High dose; HuM291; HuM291); Hulio; Human Anti-TNF IgG1 Monoclonal Antibody; Human Anti-TNFalfa; Human anti-IP10 monoclonal antibody; Human anti-TNF-alpha monoclonal antibody; Humanized recombinant IgG4 monoclonal antibody against CD-127; Humira; Humira (adalimumab original); Humira 40 mg solution for injection in pre-filled syringe; Humira 40 mg solution for injection in pre-filled syringes; Humira 40 mg/0.8 ml solution for injection; Humira 40 mg/0.8 ml solution for injection for paediatric use; Humira®; Hyaluronate; Hydrocortisone; Hydrocortisone acetate; Hydrocortisone sodium succinate; Hydrogen; Hydroxide; Hydroxocobalamin; Hydroxocobalamin with Butyrate; IBD98-M; IBD98-M Delayed-release Capsules; IDOFORM®Travel; IM90838; IMU-838; INCB039110; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN-2; ITACITINIB ADIPATE; IV Corticosteroid; Iberogast N; Imolope; Impact; Imuran; Imurek; Imurek 25mg Filmtabletten; Imurek 50mg Filmtabletten; Imurel; Inflectra; Inflectra 100 mg; Inflectra 100 mg powder for concentrate for solution for infusion; Infliximab; Infliximab (IFX); Infliximab 10 mg/kg; Infliximab 5 mg/kg; Infliximab [infliximab biosimilar 3]; Infliximab and adalimumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab, adalimumab, certolizumab pegol; Innovator infliximab; Inositol; Interferon beta; Interferon beta-1a; Interferon-beta; Interferon-beta-1a; Interferon-beta-1a, 44 microgram; Interferon-beta-1a, 66 microgram; Interleukin 2; Interleukin-2 (aldesleukin).; Iron; Iron Sucrose; Iron sucrose; Iron sulphate; Iron sulphate 200mg coated tablets; Iron supplement 300-600 mg/day; Iron(III)- hydroxide dextran complex; Itacitinib; JNJ-54781532 150 mg once daily; JNJ-54781532 25 mg once daily; JNJ-54781532 75 mg once daily; JNJ-54781532 75 mg twice daily; JNJ-54781532-AAD-10 mg; JNJ-54781532-AAD-30 mg; JNJ-54781532-AAD-5 mg; JNJ-66525433; K(D)PT; KHK4083; KRP203; KRP203A; Kamillenblüten 3ml/10ml; Kappaproct; KdPT; Kremezin; Kremezin®, Spherical Adsorptive Carbon; Kyo-Dophilus; Kümmel 2ml/10ml; L-Carnitine; L-Lysyl-D-Prolyl-L-Threonine Acetate; L-Lysyl-D-Prolyl-LThreonine acetate, lyophilisate; LC51-0255; LDP-02; LIXACOL; LOPERAMIDE; LT-02; LT-02 (modified-release PC pellets); LX1606; LY3074828; LYC-30937; LYC-30937-EC; LYS006; Lactated Ringers; Lactobacillus GG; Lactobacillus casei DG; Lactobacillus plantarum; Lactobacillus reuteri; Lactobacillus rhamnosus GG ATCC 53103; Lactobacillus salivarius UCC118; Lactobacilus acidophilus & bifidobacterium animalis/lactis; Lactose; Lactose in water; Leucine; Levocarnitine; Levocarnitine propyl hydrochloride; Linaclotide; Lixacol; Loperamide; Loperamide hydrochloride; Losartan; Low Dose Budesonide; Low FODMAP; Low dose; Low dose naltrexone; Lumbar puncture; Lysine; Lysine-D-Proline-Threonine; Lysine-D-proline-threonine; MATRICARIA FLOWER; MATRICARIA RECUTITA L. FLOS; MD-0901; MDX-1100; MDX-1100 (anti-CXCL10 human monoclonal antibody); MEDI7183 high dose; MEDI7183 low dose; MEDI7183 medium dose; MELISSAE FOLII DRY AQUEOUS EXTRACT; MENTHA × PIPERITA L. FOLIUM; MERCAPTOPURINE; MESALAZINA; MESALAZINE; MESENCHYMAL CELLS; MET-2; METHOTREXATE; METHOTREXATE DISODIUM; METHYLENE BLUE; METHYLPREDNISOLONE SODIUM HEMISUCCINATE; MEZAVANT; MIRIKIZUMAB; MK-8259; MLN0002; MLN0002 (Vedolizumab); MLN0002 SC; MLN002; MMX Mesalamine; MMX Mesalamine/Mesalazine; MMX Mesalamine/Mesalazine (High Dose); MMX Mesalamine/Mesalazine (Low Dose); MMX mesalamine/ mesalazine; MONOCLONAL ANTIBODY ANTI-IGG1; MSC; MTX; MTX 12.5; MTX 25; MYRRH; Magnesium; Magnesium citrate; Maltodextrin; Maltose; Mango; Mango polyphenolics; Mare´s milk; Matricaria Flower; Maximal oral 5ASA; Melatonin; Melissenblätter 15ml/10ml; Melitracen; Mercaptopurine; Mercaptopurine (Puri-Nethol); Mercaptopurine (Purinethol); Mesalamin; Mesalamine; Mesalamine Delayed Release Tablets 400mg; Mesalamine Enema; Mesalamine Granules; Mesalamine Once-Daily; Mesalamine Twice-Daily; Mesalamine granules; Mesalamine, 5-ASA; Mesalamine, 5-aminosalicylic acid [5-ASA]; Mesalazina; Mesalazine; Mesalazine (3,600 mg); Mesalazine (Asacol®); Mesalazine - TID 1000 mg; Mesalazine - TID 2x 500 mg; Mesalazine 1000 mg gastro-resistant tablets; Mesalazine 250Mg; Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet; Mesalazine 4G Enema; Mesalazine 500 mg gastro-resistant tablets (Salofa; Mesalazine 500 mg gastro-resistant tablets (Salofalk® 500 mg); Mesalazine Enema; Mesalazine enema; Mesalazine liquid enema; Mesalazine slow-release granules; Mesalazine tablet; Mesalazine with hydrocortisone sodium succinate; Mesalazinum; Mesenchymal Stromal Cells; Mesenchymal stromal cells; Methotrexate; Methotrexate bellon; Methotrexate bellon 25mg/ml; Methotrexate injection; Methylene blue; Methylene blue 25mg tablets; Methylprednisolone; Metoject; Metronidazole; Metronidazole capsule 50 mg; Mezavant; Mezavant 1200 mg magensaftresistente Retardtabletten; Mezavant Gastro-resistant, prolonged release tablets; Mezavant XL; Mezavant XL 1200 mg gastro-resistant prolonged release tablets; Mezavant XL 1200 mg gastro-resistant, prolonged release tablets; Mezavant XL 1200 mg gastro-resistant, prolonged release tablets.; Mezavant XL 1200mg gastro-resistant, prolonged release tablets; Mezavant XL Gastro-resistant, prolonged release tablets; Midazolam; Midazolam 2 mg; Mirikizumab; Mirikizumab IV; Mirikizumab SC; MitoQ; Modified Gegen Qinlian Decoction; Modified-release phosphatidylcholine; Mongersen; MultiStem; MultiStem high dose; MultiStem low dose; Multiple dose- Group B; Multiple dose-Group B; Multistem; Mycodigest supplement; Myrrh; Myrrhinil-Intest®; N.a.; NAND (Neoandrographolide); ND; NEORAL; NX-13 250 mg; Naltrexone; Nanocort; Neomycin; Neoral Soft Gelatin Capsules; Niclosamide; Nicolon; Nitazoxanide; Nitazoxanide 500Mg Oral Tablet; Nivolumab; Nolpitantium Besylate; Nolpitantium besylate; Non as of yet; None; None given; Normal Saline Enema; Null; Nutrition supplement; Nutritional dietary intervention; Nuvion®); OPC-6535; OPC-6535 Tablets (drug); OPC-6535(Tetomilast); OPRX-106; OPRX-106 (plant cells expressing TNFR-Fc) 2mg; OPRX-106 (plant cells expressing TNFR-Fc) 8mg; ORE1001; OSE-127; OST-122; Oats; Omeprazole; Omeprazole 20 mg; Ondansetron; Ondansetron hydrochloride dihydrate; Ontamalimab; Oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone; Oral Corticosteroids; Oral OKT3; Orencia; Originator (legacy) drug; Oseltamivir; Other: 0 mg; Other: 100% pomegranate juice; Other: Additional Therapies; Other: Control; Other: Control group(Normal saline); Other: Conventional drugs; Other: Faecal bacterial transplantation; Other: Fast Mimicking Diet; Other: Hyperbaric Oxygen Therapy; Other: Impact of biotherapy on postoperative morbidity in ulcerative colitis; Other: Intensify treatment with the existing drug; Other: Laboratory Biomarker Analysis; Other: Measurement of drug (Adalimumab/Infliximab); Other: Mesalazine; Other: Other Biologic Agents; Other: PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA); Other: Saline; Other: Therapy Education; Other: Threonine; Other: Ulcerative Colitis Diet; Other: dietary intervention with no-carrageenan diet; Other: e-Monitoring; Other: pretreatment antibiotics; Overencapsulated Azathioprine (Imuran) 50 mg Tablet; Overencapsulated mesalazine tablets; Oxygen; Ozanimod; Ozanimod hydrochloride; PARNAPARIN SODIUM; PBF-677; PCT (PureCell Technologies Complex); PEG; PEG-liposomal prednisolone sodium phosphate; PF 06687234; PF-00547659; PF-00547659 SC Injection; PF-05230917; PF-05285401; PF-06480605; PF-06480605 100 mg/ml; PF-06651600; PF-06651600 10 mg; PF-06651600 50 mg; PF-06651600-15; PF-06687234; PF-06700841; PF-06700841 25 mg; PF-06700841 5 mg; PF-06700841-15; PF-06826647; PF-06826647 100 mg QD; PF-06826647 300 mg QD; PF-06826647 600 mg QD; PF-6826647 400 mg QD; PN-10884A; PN-943; PRD5973697; PREDNISOLONE; PREDNISOLONE SODIUM PHOSPHATE; PREDNISONE; PRIM-DJ2727; PRO145223; PRO145223 (RO5490261); PROPIONYL L-CARNITINE; PROPIONYL L-CARNITINE HYDROCHLORIDE; PRV-300; PS; PS-QD; PS-SP; PTG-100; PUR 0110; PUR 0110 Rectal Enema; PUR 0110 Rectal Enema 1000 mg; PUR 0110 Rectal Enema 250 mg; PUR 0110 Rectal Enema 500 mg; PV; Palmitoleic Acid; Palmitoleic acid; Parnaparin; Pending; Pentasa; Pentasa 2g sachet prolonged release granules (95%); Pentasa 500 mg Retardtabletten; Pentasa Compact 2g, granulate with prolonged release; Pentasa Compact 4g, granulate with prolonged release; Pentasa Sachet; Pentasa Sachet 1 g; Pentasa Sachet 1g; Pentasa Sachet 2 g; Pentasa enema; Pentasa prolonged release granules 2g; Pentasa sachet 1g; Pfefferminzblätter 1ml/10ml; Phosphate; Phosphatidylcholine; Photodynamic therapy with Gliolan; Picosulfate; Placebo; Polaprezinc; Polyethylene glycol; Polyphenon E®; Pomegranate; Prednisolon; Prednisolon Jenapharm; Prednisolone; Prednisolone Sodium Phosphate; Prednisolone Tablets B.P. 5mg; Prednisolone sodium metasulphobenzoate; Prednisone; Prefilled Syringe delivery of Golimumab; Previously referred to as MEDI2070 and AMG 139; Probiotic; Probiotic Formula Capsule; Probiotic Mixture; Probiotics; Procedure: Biopsies; Procedure: Blood sampling, endoscopy; Procedure: Colectomy; Procedure: Colonoscopy; Procedure: Colorectal biopsies; Procedure: Enema; Procedure: FMT; Procedure: Fecal microbiota transplantation; Procedure: Gastroscopy; Procedure: Hyperbaric oxygen; Procedure: Infusion of Saline; Procedure: Narrow Band Imaging; Procedure: Rectal dialysis; Procedure: Sham Hyperbaric Air; Procedure: Standardized FMT; Procedure: Stool samples; Procedure: colonoscopy; Procedure: lumbar puncture; Procedure: rectosigmoidoscopy; Procedure: sigmoidoscopy; Products containing aminosalicylate; Products containing azathioprine or 6-mercaptopurine; Proline; Promiten; Propionyl-L-Carnitine; Propionyl-L-carnitine; Propionylcarnitinhydrochlorid; Psyllium; Psyllium Husk Powder; Psyllium husk; Puri-Nethol; QBECO SSI; RAVAGALIMAB; RDP58; RECTABUL2mg rectal form; REMICADE; REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO; RIBOFLAVIN; RISANKIZUMAB; RO5490261 / F02; RO5490261/F02; RO5490261/F04-02; RO7049665; RO7246311; ROSUVASTATIN CALCIUM; RPC1063; RTNV148B IgG; Raspberry; Ravagalimab; Rebamipide; Recombinant Factor XIII (rFXIII); Rectal dialysis; Rectal tacrolimus; Regular treatment; Remestemcel-L; Remicade; Remicade (infliximab); Remicade 100 mg infuusiokuiva-aine, konsentraattiliuosta varten; Remicade 100 mg powder for concentrate for solution for infusion.; Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning; Remsima; Remsima (CT-P13); Remsima (infliximab); Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning; Remsima and Inflectra; Retarded Release Phosphatidylcholine (rPC); Retarded release phosphatidylcholine; RhIL-11; RhuMAb Beta7; RhuMAb Beta7, Anti Beta 7, PRO145223; RhuMAb Beta7, Anti Beta7, PRO145223; RhuMab Beta7, Anti Beta7, PRO145223; Riboflavin; Rifaximin; Risankizumab; Risankizumab (Genetical Recombination); Risankizumab IV; Risankizumab SC; Rituximab; Rivenprost; Rivenprost (drug); Ro 549-0261/F04; Rosiglitazone; Rosuvastatin; Rosuvastatine EG; SANDINUM; SAR339658; SB-656933; SB-656933 Tablets; SB012; SB5; SC12267; SC12267 (4SC-101); SCH 900050; SER-287; SF257 C59; SHINGRIX; SHP647; SHR0302; SIMPONI; SODIUM HYALURONATE; SOYBEAN PHOSPHATIDYLCHOLINE; SPD476; SPD476 (mesalazine); SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine; SPESOLIMAB; SR140333B; SRT2104; ST 261; ST-0529; ST10-021; ST261; STELARA®; STNM01; STNM01 1.84 mg; STW5-II; STW5-II (Iberogast N, BAY98-7410); SUSPENSION CONTAINING 7500 EMBRYONATED VIABLE TRICHURIS SUIS OVA/15ML; Salicylic acid; Saline; Salmon; Salofalk; Salofalk 1000mg Granu-Stix; Salofalk 1000mg Granu-Stix®; Salofalk 1000mg Granu-stix®; Salofalk 3g gastro-resistant prolonged-release granules; Salofalk 4g/60ml Klysma; Salofalk Granu-Stix 500 mg; Salofalk® 1000mg Granu-Stix®; Salofalk® 500 mg gastro-resistant tablet; Salofalk® 500 mg tablets; Salofalk® 500mg; Salofalk® 500mg Granu-Stix®; Sandimmum; Sandimmun; Sandimmun 50 mg/ml, infuusiokonsentraatti; Sandimmun Neoral; Semi-vegetarian diet; Serum bovine immunoglobulin; Shingrix; Simponi; Simponi (Golimumab); Simponi®; Simponi® (Golimumab); Simulect; Single dose-group A; Smartject Device delivery of Golimumab; Smoking cigarettes; Smoking of cannabis; Sodium Picosulfate/Magnesium Citrate Laxative; Solu-Medrol; Solu-medrol; Sotrastaurin; Sotrastaurin (INN) acetate; Soybean; Spesolimab; Spesolimab IV infusion; Spesolimab SC solution for injection; Standard 2 hours-infusion; Standard Therapy; Standardized FODMAP; Standardized anthocyanin-rich extract; Stasis; Stelara; Sterile saline for injection; Steroids; Sucrose; Sugar Extract; Sulphsalazine, Pentasa, Asacol, Colazide, Depentum; Suspension de microbiote fécal; Synergy-1; Synergy1; Sübetaholzwurzel 1ml/10ml; Süßholzwurzel 1ml/10ml; TA-650; TA-650 (Infliximab); TD-1473; TD-1473 Dose A; TD-1473 Dose B; TD-1473 Dose C; TD-3504; THRX-139060; TJ301 300mg; TJ301 600mg; TOFACITINIB; TOP1288; TOP1288 Rectal solution; TOP1288 rectal solution; TP05; TP05 Coating A; TP05 Coating B; TP05 Coating D; TP05 Coating E; TP05 Coating H; TREMFYA®; TSO; Tacrolimus; Tauroursoursodeoxycholic acid, brand name Tudcabil; Telotristat; Telotristat Etiprate; Telotristat etiprate; Terbinafine; Tetomilast; Tetracycline; Thalidomide; Thalidomide Pharmion; Threonine; To be confirmed; To be requested; Tofacitinib; Tofacitinib citrate; Tofacitinib citrate (Phase III Formulation); Tofacitinib citrate (Proposed commercial formulation - debossed); Tofacitinib citrate (Proposed commercial formulation – debossed); Tofacitinib citrate (Proposed commercialFormulation - debossed); Tofacitinib citrate (clinical trial image); Traditional treatments; Tralokinumab; Treatment Algorithm A; Treatment Algorithm B; Treatment Algorithm C; Tremfya; Trexan; Trexan inj 25 mg/ml; Trichuris suis eggs; Trichuris suis ova; Trichuris suis ova (TSO); Tris; UCB4940; UCMSC group; UDCA; UR-12746-S; USTEKINUMAB; UTTR1147A; UTTR1147A, IL22-Fc, IL-22Fc; UTTR1147A/RO7021610 (Active); Umbilical Cord Mesenchymal Stem Cells; Unknown; Upadacitinib; Upadacitinib (ABT-494); Upadacitinib - Direct compression-yellow; Upadacitinib - Wet Granulation-Yellow; Upadacitinib -Direct compression-yellow; Updacitinib (ABT-494); Urbason; Ursodeoxycholic acid; Ursodiol; Ursodiol (ursodeoxycholic acid, UDCA); Ursofalk; Ustekinumab; Ustekinumab Dose Based on BSA and Body Weight; Ustekinumab IV; Ustekinumab IV Infusion; Ustekinumab SC; Ustekinumab SC Injection; Usual current care; V565; VB-201; VB-201 160mg; VEDOLIZUMAB; VSL#3; VSL#3 (Original De Simone formulation); VSL#3®; Vaccine Vivotif + Vaccine Dukoral; Vaccine Vivotif + Vaccine Dukoral + oats; Valganciclovir; Vaminolac; Vaminolac, komb.; Vamorolone; Vamorolone 4% suspension for oral dosing; Vancomycin; Vancomycin Pre-Treat; Vancomycin Pre-Treatment; Vatelizumab; Vedolizumab; Vedolizumab 108 mg SC; Vedolizumab 300 mg; Vedolizumab 300 mg IV; Vedolizumab IV; Vedolizumab IV, Placebo IV, Placebo SC; Vedolizumab IV, Placebo SC; Vedolizumab Injection; Vedolizumab Intravenous (IV), Vedolizumab Subcutaneous (SC), Placebo IV; Vedolizumab SC; Vedolizumab SC 108 mg; Vedolizumab intravenous injection; Vedolizumab subcutaneous injection; Vidofludimus; Vidofludimus calcium; Vidofludimus calcium dihydrate; Vigantol; Vigantol Oel; Vigantol Oel TM; Visilizumab; Visilizumab (HuM291; Visilizumab (Nuvion); Visilizumab (Nuvion®; Vitamin B2; Vitamin D; Vitamin D drops; Vitamin D3; Vitamin E; Vitamin E 800IU; Vitamin K; Vitamin K 10 mg; Vivotif; Warfarin; Warfarin 10 mg; Water; Wharton Jelly Mesenchymal stem cells; XELJANZ; Xeljanz; Xeljanz 5 mg film-coated tablets; Xeljanz 5mg film-coated tablets; Z-206; Zessly; Zoenasa-1:4; [124I]IB PF 06687234; [14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration; [18F]FSPG; [BI 655130]; [CC-10004]; [N/A]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04624230 (ClinicalTrials.gov)	November 20, 2020	26/10/2020	Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis	OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS	Ulcerative Colitis	Drug: tofacitinib	Pfizer	NULL	Not yet recruiting	2 Years	17 Years	All	120	Phase 3	NULL
2	NCT04505410 (ClinicalTrials.gov)	November 18, 2020	5/8/2020	A Fasting Mimicking Diet on Ulcerative Colitis Patients Undergoing Tofacitinib Induction	A Randomized Control Study to Examine the Influence of a Fasting Mimicking Diet on Moderate to Severe Ulcerative Colitis Patients Undergoing Tofacitinib Induction	Ulcerative Colitis	Drug: Tofacitinib;Other: Fast Mimicking Diet	University of Miami	Pfizer	Recruiting	18 Years	N/A	All	76	Phase 3	United States
3	EUCTR2020-004391-18-FR (EUCTR)	28/10/2020	14/09/2020	IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS	IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS - VASC-UC	ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Inflectra 100 mg Product Name: Inflectra 100 mg Trade Name: AMGEVITA Product Name: AMGEVITA Trade Name: Simponi Product Name: Simponi Trade Name: Entyvio 300 mg Product Name: Entyvio 300 mg Trade Name: XELJANZ Product Name: XELJANZ	CHU Amiens-Picardie	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 4	France
4	EUCTR2020-002695-12-NL (EUCTR)	14/10/2020	02/09/2020	Treatment of refractory pouchitis with tofacitinib	Tofacitinib in the treatment of chronic, recurrent and/or antibiotic refractory pouchitis: a multi-omics approach - TOFA-Pouchitis	Chronic, recurrent and/or antibiotic refractory pouchitis in patients with ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Xeljanz 5mg film-coated tablets	Amsterdam UMC, location AMC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	Netherlands
5	NCT04424303 (ClinicalTrials.gov)	September 30, 2020	8/6/2020	Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis	Evaluation of the Clinical Benefit of ToFAcitinib Treatment in Patients With Moderate to Severe Ulcerative Colitis Under Real-life Conditions of Use: TOFAst Study	Ulcerative Colitis	Drug: Tofacitinib	Pfizer	NULL	Not yet recruiting	18 Years	N/A	All	280		NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT04338204 (ClinicalTrials.gov)	September 14, 2020	4/4/2020	Observational Study To Assess The Effectiveness Of Tofacitinib In Ulcerative Colitis In Clinical Practice In Sweden	Observational Study of Tofacitinib in Ulcerative Colitis in Sweden (ODEN)	Ulcerative Colitis	Drug: tofacitinib	Pfizer	NULL	Recruiting	18 Years	99 Years	All	120		Sweden
7	EUCTR2019-004652-11-SI (EUCTR)	28/08/2020	31/08/2020	A Study of Etrolizumab-Based Induction Therapy Combinations Followed by Etrolizumab Maintenance Therapy in Patients with Moderate-To-Severe Ulcerative Colitis	RANDOMIZED, OPEN-LABEL PHASE 3B STUDY OF ETROLIZUMAB BASED INDUCTION THERAPY COMBINATIONS FOLLOWED BY ETROLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS - Lantana	Ulcerative Colitis (UC) MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Etrolizumab Product Code: RO5490261/F04-02 INN or Proposed INN: Etrolizumab Other descriptive name: rhuMAb Beta7, Anti Beta7, PRO145223 Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Other descriptive name: INFLIXIMAB Trade Name: Xeljanz INN or Proposed INN: TOFACITINIB Other descriptive name: TOFACITINIB Trade Name: Xeljanz INN or Proposed INN: TOFACITINIB Other descriptive name: TOFACITINIB Trade Name: Stelara INN or Proposed INN: USTEKINUMAB Other descriptive name: USTEKINUMAB Trade Name: Stelara INN or Proposed INN: USTEKINUMAB Other descriptive name: USTEKINUMAB	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	372	Phase 3	Serbia;United States;Slovakia;Spain;Ukraine;Ireland;Israel;Russian Federation;Italy;Switzerland;France;Latvia;Netherlands;Slovenia;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Canada;Argentina;Brazil;Belgium;Poland;Germany
8	NCT04576000 (ClinicalTrials.gov)	August 25, 2020	17/9/2020	Identification of Biomarkers of Tofacitinib Therapy in Patients With Ulcerative Colitis	PhaRmacOkinetics and PHarmacodynamic BiomarkErs of TofacItinib Therapy in Patients With Ulcerative Colitis (PROPHETIC)	Ulcerative Colitis	Drug: Tofacitinib	Robarts Clinical Trials Inc.	NULL	Recruiting	18 Years	N/A	All	100		United States;Belgium;Canada;Italy;Netherlands;Spain
9	EUCTR2019-003780-21-NL (EUCTR)	04/05/2020	21/02/2020	An investigation of tofacitinib in patients with ulcerative colitis	Pharmacokinetics and Pharmacodynamic Biomarkers of Tofacitinib Therapy in Patients with Ulcerative Colitis (PROPHETIC Study)	Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: XELJANZ Product Name: XELJANZ INN or Proposed INN: TOFACITINIB	Robarts Clinical Trials	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 4	United States;Canada;Spain;Belgium;Netherlands;Italy
10	EUCTR2018-004890-28-IT (EUCTR)	09/10/2019	07/10/2020	Study for the research of predictive factors of response to Tofacitinib therapy in patients with ulcerative rectal colitis.	(A)nalysis of immunological (VA)riables in ex vivo (T)ofacitinib-treated human biopsies from (A)ctive ulcerative colitis patients to predict clinical (R)esponse (the AVATAR study). - AVATAR	Ulcerative colitis MedDRA version: 20.0;Level: LLT;Classification code 10045282;Term: UC;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Xeljanz Product Name: Xeljanz Product Code: [N/A]	DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 4	Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	NCT03591770 (ClinicalTrials.gov)	July 31, 2019	9/7/2018	Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib	The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib	Inflammatory Bowel Diseases	Biological: SHINGRIX	Boston Medical Center	NULL	Suspended	50 Years	N/A	All	100	Phase 4	United States
12	EUCTR2018-004587-61-NL (EUCTR)	23/04/2019	13/05/2019	Characterization of lipid changes in patients with ulcerative colitis treated with tofactinib or infliximab	Deep profiling of lipid changes in patients with active ulcerative colitis treated with either tofacitinib or infliximab - LIPID	Ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Erasmus Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 4	Netherlands
13	EUCTR2017-002274-39-NL (EUCTR)	27/06/2018	19/12/2017	A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission	A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: XELJANZ Product Name: Tofacitinib citrate Product Code: CP -690,550 -10 INN or Proposed INN: tofacitinib Other descriptive name: CP -690,550	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3;Phase 4	United States;Serbia;Slovakia;Spain;Ukraine;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Belgium;Poland;South Africa;Netherlands;Germany;Japan;New Zealand;Korea, Republic of
14	EUCTR2017-002274-39-GB (EUCTR)	12/04/2018	20/12/2017	A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission	A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3;Phase 4	Serbia;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;South Africa;Netherlands;Germany;New Zealand;Japan;Korea, Republic of
15	EUCTR2017-002274-39-BE (EUCTR)	22/02/2018	18/12/2017	A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission	A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: XELJANZ Product Name: Tofacitinib citrate Product Code: CP -690,550 -10 INN or Proposed INN: tofacitinib Other descriptive name: CP -690,550	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3;Phase 4	United States;Poland;Serbia;South Africa;Czechia;Germany;Slovakia;Spain;Ukraine;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Netherlands;Japan;New Zealand;Korea, Republic of;Canada;Belgium
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	EUCTR2017-002274-39-CZ (EUCTR)	16/01/2018	14/12/2017	A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission	A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: XELJANZ Product Name: Tofacitinib citrate Product Code: CP -690,550 -10 INN or Proposed INN: tofacitinib Other descriptive name: CP -690,550	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3;Phase 4	Serbia;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;South Africa;Netherlands;Germany;New Zealand;Japan;Korea, Republic of
17	EUCTR2017-002274-39-AT (EUCTR)	04/01/2018	20/12/2017	A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission	A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: XELJANZ Product Name: Tofacitinib citrate Product Code: CP -690,550 -10 INN or Proposed INN: tofacitinib Other descriptive name: CP -690,550	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	130	Phase 3	Serbia;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;South Africa;Netherlands;Germany;New Zealand;Japan;Korea, Republic of
18	EUCTR2017-002274-39-HU (EUCTR)	21/12/2017	19/12/2017	A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission	A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: XELJANZ Product Name: Tofacitinib citrate Product Code: CP -690,550 -10 INN or Proposed INN: tofacitinib Other descriptive name: CP -690,550	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3;Phase 4	United States;Serbia;Slovakia;Spain;Ukraine;Austria;Russian Federation;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Belgium;Poland;South Africa;Germany;Netherlands;Japan;New Zealand;Korea, Republic of
19	EUCTR2017-002274-39-ES (EUCTR)	21/12/2017	22/12/2017	A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission	A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: XELJANZ Product Name: Tofacitinib citrate Product Code: CP -690,550 -10 INN or Proposed INN: tofacitinib Other descriptive name: CP -690,550	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	Serbia;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;South Africa;Netherlands;Germany;New Zealand;Japan;Korea, Republic of
20	EUCTR2017-002274-39-SK (EUCTR)	08/12/2017	27/10/2017	A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission	A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: XELJANZ Product Name: Tofacitinib citrate Product Code: CP -690,550 -10 INN or Proposed INN: tofacitinib Other descriptive name: CP -690,550	Pfizer Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3;Phase 4	United States;Serbia;Slovakia;Spain;Ukraine;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Belgium;South Africa;Germany;Netherlands;Japan;New Zealand;Korea, Republic of
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
21	NCT03281304 (ClinicalTrials.gov)	November 16, 2017	11/9/2017	A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission	A PHASE 3B/4,MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION	Ulcerative Colitis	Drug: CP -690,500 5 mg;Drug: CP -690,550 10 mg	Pfizer	NULL	Active, not recruiting	18 Years	N/A	All	141	Phase 4	United States;Belgium;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom
22	EUCTR2016-002691-27-NL (EUCTR)	19/10/2017	01/06/2017	An open label study to study changes in the structure of the mucosa of the bowel in subjects during treatment with tofacitinib for moderate to severe ulcerative colitis	An open label exploratory analysis of the histological, immunological and microbiome changes of the colonic mucosa during treatment with tofacitinib for moderate-severe ulcerative colitis - TOFA-histo	Ulcerative colitis MedDRA version: 20.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Xeljanz 5 mg film-coated tablets	Academic Medical Center	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 3	Netherlands
23	NCT03103412 (ClinicalTrials.gov)	May 4, 2017	24/3/2017	TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)	Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD-3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)	Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects	Drug: TD-3504;Drug: 15N2-tofacitinib;Drug: Placebo	Theravance Biopharma	NULL	Completed	18 Years	55 Years	All	32	Phase 1	United States
24	EUCTR2011-004579-35-HR (EUCTR)	27/08/2013	28/08/2014	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand
25	EUCTR2011-004581-14-HR (EUCTR)	26/08/2013	28/08/2014	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	725		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
26	EUCTR2011-004580-79-HR (EUCTR)	26/08/2013	28/08/2014	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan
27	EUCTR2011-004578-27-HR (EUCTR)	26/08/2013	28/08/2014	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
28	EUCTR2011-004578-27-NL (EUCTR)	04/03/2013	12/03/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 15.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Poland;Belgium;Brazil;Romania;Croatia;Germany;Japan;United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada
29	EUCTR2011-004581-14-IT (EUCTR)	18/01/2013	07/08/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis (UC) MedDRA version: 14.1;Level: LLT;Classification code 10045282;Term: UC;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1;Level: SOC;Classification code 10017947;Term: Gastrointestinal disorders;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: NA Product Code: CP -690,550-10 Other descriptive name: tofacitinib Product Name: NA Product Code: CP -690,550-10 Other descriptive name: tofacitinib	PFIZER LIMITED	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	725		United States;Estonia;Taiwan;Spain;Ukraine;Austria;Russian Federation;Israel;Colombia;United Kingdom;Italy;India;Hungary;Czech Republic;Canada;Brazil;Denmark;Australia;South Africa;Germany;Netherlands;Latvia;Japan;Korea, Republic of
30	EUCTR2011-004580-79-IT (EUCTR)	18/01/2013	07/08/2012	maintenance therapy with CP-690,550 in subjects with ulcerative colitis	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	ulcerative colitis (UC) MedDRA version: 14.1;Level: LLT;Classification code 10045282;Term: UC;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1;Level: SOC;Classification code 10017947;Term: Gastrointestinal disorders;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: NA Product Code: CP -690,550-10 Other descriptive name: tofacitinib Product Name: NA Product Code: CP -690,550-10 Other descriptive name: tofacitinib	PFIZER LIMITED	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	654		United States;Taiwan;Estonia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;Australia;Denmark;South Africa;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Brazil;Croatia;Germany;New Zealand;Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
31	EUCTR2011-004578-27-IT (EUCTR)	18/01/2013	07/08/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulverative colitis MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: NA Product Code: CP -690,550-10 Other descriptive name: tofacitinib Product Name: NA Product Code: CP -690,550-10 Other descriptive name: tofacitinib	PFIZER INC.	NULL	Not Recruiting			Female: yes Male: yes	545		United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Korea, Democratic People's Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Croatia;Germany;Japan
32	EUCTR2011-004579-35-NL (EUCTR)	10/10/2012	12/03/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 15.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Brazil;Romania;Croatia;Germany;New Zealand
33	EUCTR2011-004581-14-NL (EUCTR)	10/10/2012	12/03/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Tofacitinib citrate (clinical trial image) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib Product Name: Tofacitinib citrate (Proposed commercial formulation - debossed) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	Serbia;United States;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Italy;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Belgium;Poland;Croatia;Romania;Germany;New Zealand
34	EUCTR2011-004578-27-PL (EUCTR)	18/09/2012	20/06/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Brazil;Belgium;Poland;Romania;Croatia;Germany;New Zealand;Japan
35	EUCTR2011-004581-14-PL (EUCTR)	17/09/2012	22/06/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Tofacitinib citrate (clinical trial image) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib	Pfizer Inc., 235 East 42nd Street, New York, New York 10017, United States	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
36	EUCTR2011-004579-35-PL (EUCTR)	17/09/2012	28/06/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Brazil;Belgium;Poland;Romania;Croatia;Germany;New Zealand
37	EUCTR2011-004580-79-PL (EUCTR)	05/08/2012	12/06/2012	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 18.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Brazil;Belgium;Poland;Romania;Croatia;Germany;New Zealand;Japan
38	EUCTR2011-004578-27-ES (EUCTR)	11/07/2012	09/03/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Belgium;Brazil;Romania;Croatia;Germany;Japan
39	EUCTR2011-004579-35-ES (EUCTR)	11/07/2012	09/03/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Belgium;Brazil;Romania;Croatia;Germany;New Zealand
40	EUCTR2011-004579-35-CZ (EUCTR)	29/06/2012	08/02/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc	,NULL	Not Recruiting			Female: yes Male: yes	545	Phase 3	United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Belgium;Brazil;Romania;Croatia;Germany;New Zealand
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
41	EUCTR2011-004581-14-CZ (EUCTR)	29/06/2012	08/02/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Tofacitinib citrate (clinical trial image) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib Product Name: Tofacitinib citrate (Proposed commercial formulation - debossed) Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc.	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;Japan;New Zealand
42	EUCTR2011-004578-27-CZ (EUCTR)	29/06/2012	08/02/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc	,NULL	Not Recruiting			Female: yes Male: yes	545	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
43	EUCTR2011-004580-79-CZ (EUCTR)	26/06/2012	08/02/2012	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan;Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy
44	EUCTR2011-004579-35-BE (EUCTR)	08/06/2012	08/03/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 16.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Belgium;Brazil;Romania;Croatia;Germany;New Zealand
45	EUCTR2011-004580-79-BE (EUCTR)	08/06/2012	07/03/2012	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
46	EUCTR2011-004581-14-BE (EUCTR)	07/06/2012	07/03/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Tofacitinib citrate (clinical trial image) Product Code: CP -690,550-10 Other descriptive name: tofacitinib Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed) Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	900	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
47	EUCTR2011-004578-27-BE (EUCTR)	06/06/2012	07/03/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
48	EUCTR2011-004580-79-DE (EUCTR)	06/06/2012	28/03/2012	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 INN or Proposed INN: not available Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Germany;New Zealand;Japan;Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia
49	NCT01458951 (ClinicalTrials.gov)	June 2012	21/10/2011	A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis	A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.	Ulcerative Colitis	Drug: tofacitinib;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	547	Phase 3	United States;Australia;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Korea, Republic of;Latvia;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom
50	EUCTR2011-004578-27-HU (EUCTR)	30/05/2012	10/02/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
51	EUCTR2011-004579-35-DE (EUCTR)	29/05/2012	21/03/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 INN or Proposed INN: not available Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA	NULL	Not Recruiting			Female: yes Male: yes	545	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand
52	EUCTR2011-004578-27-LV (EUCTR)	23/05/2012	01/03/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
53	EUCTR2011-004578-27-DE (EUCTR)	23/05/2012	05/03/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 INN or Proposed INN: not availble Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA	NULL	Not Recruiting			Female: yes Male: yes	545	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
54	EUCTR2011-004579-35-LV (EUCTR)	23/05/2012	01/03/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand
55	EUCTR2011-004581-14-LV (EUCTR)	23/05/2012	01/03/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	725	Phase 3	United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
56	EUCTR2011-004580-79-LV (EUCTR)	23/05/2012	01/03/2012	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan
57	EUCTR2011-004578-27-AT (EUCTR)	18/05/2012	27/03/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 INN or Proposed INN: not available Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
58	EUCTR2011-004580-79-AT (EUCTR)	18/05/2012	27/03/2012	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 18.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 INN or Proposed INN: not available Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan
59	EUCTR2011-004581-14-ES (EUCTR)	18/05/2012	14/03/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	725		United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;Japan
60	EUCTR2011-004580-79-ES (EUCTR)	18/05/2012	09/03/2012	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Belgium;Brazil;Romania;Croatia;Germany;Japan;New Zealand;United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
61	EUCTR2011-004581-14-AT (EUCTR)	18/05/2012	27/03/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Serbia;Estonia;Taiwan;Slovakia;Spain;Ukraine;Israel;Russian Federation;Italy;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;New Zealand
62	EUCTR2011-004579-35-AT (EUCTR)	18/05/2012	21/03/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 INN or Proposed INN: not available Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand
63	EUCTR2011-004581-14-HU (EUCTR)	10/05/2012	10/02/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Tofacitinib citrate (clinical trial image) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;Japan
64	EUCTR2011-004579-35-HU (EUCTR)	10/05/2012	10/02/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand
65	EUCTR2011-004580-79-HU (EUCTR)	10/05/2012	10/02/2012	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
66	EUCTR2011-004580-79-SK (EUCTR)	03/05/2012	10/04/2013	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan
67	EUCTR2011-004579-35-SK (EUCTR)	02/05/2012	13/04/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand
68	EUCTR2011-004581-14-SK (EUCTR)	02/05/2012	13/04/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Tofacitinib citrate (clinical trial image) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib	Pfizer Inc.	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Serbia;Estonia;Taiwan;Slovakia;Spain;Ukraine;Israel;Russian Federation;Italy;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;New Zealand
69	EUCTR2011-004578-27-SK (EUCTR)	02/05/2012	12/04/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
70	EUCTR2011-004581-14-GB (EUCTR)	01/05/2012	01/03/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Tofacitinib citrate (clinical trial image) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	Serbia;United States;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Italy;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Belgium;Poland;Croatia;Romania;Germany;New Zealand
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
71	EUCTR2011-004579-35-GB (EUCTR)	01/05/2012	12/01/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand
72	EUCTR2011-004578-27-EE (EUCTR)	26/04/2012	14/02/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
73	EUCTR2011-004578-27-GB (EUCTR)	26/04/2012	12/01/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan
74	EUCTR2011-004581-14-EE (EUCTR)	26/04/2012	13/02/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Tofacitinib citrate (clinical trial image) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;Japan
75	EUCTR2011-004579-35-EE (EUCTR)	26/04/2012	14/02/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545		Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
76	EUCTR2011-004580-79-EE (EUCTR)	26/04/2012	13/02/2012	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan
77	NCT01465763 (ClinicalTrials.gov)	April 2012	21/10/2011	A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis	A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis	Ulcerative Colitis	Drug: tofacitinib;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	614	Phase 3	United States;Australia;Austria;Belgium;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;Brazil
78	EUCTR2011-004581-14-DK (EUCTR)	20/03/2012	09/02/2012	A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Tofacitinib citrate (clinical trial image) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed) Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	Serbia;United States;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Italy;France;Australia;Denmark;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Belgium;Poland;Croatia;Romania;Germany;New Zealand
79	EUCTR2011-004580-79-DK (EUCTR)	24/02/2012	23/01/2012	A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	654	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan
80	EUCTR2011-004579-35-DK (EUCTR)	24/02/2012	24/02/2012	A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Moderate to severe active Ulcerative Colitis MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
81	EUCTR2011-004578-27-DK (EUCTR)	24/02/2012	09/02/2012	A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.	A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Ulcerative colitis MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: CP -690,550-10 Product Code: CP -690,550-10 Other descriptive name: tofacitinib	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Not Recruiting			Female: yes Male: yes	545	Phase 3	Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04624230
(ClinicalTrials.gov)

November 20, 2020

26/10/2020

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Ulcerative Colitis

Drug: tofacitinib

Pfizer

NULL

Not yet recruiting

2 Years

17 Years

All

120

Phase 3

NULL

NCT04505410
(ClinicalTrials.gov)

November 18, 2020

5/8/2020

A Fasting Mimicking Diet on Ulcerative Colitis Patients Undergoing Tofacitinib Induction

A Randomized Control Study to Examine the Influence of a Fasting Mimicking Diet on Moderate to Severe Ulcerative Colitis Patients Undergoing Tofacitinib Induction

Ulcerative Colitis

Drug: Tofacitinib;Other: Fast Mimicking Diet

University of Miami

Pfizer

Recruiting

18 Years

N/A

All

Phase 3

United States

EUCTR2020-004391-18-FR
(EUCTR)

28/10/2020

14/09/2020

IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS

IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS - VASC-UC

ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Trade Name: Inflectra 100 mg
Product Name: Inflectra 100 mg
Trade Name: AMGEVITA
Product Name: AMGEVITA
Trade Name: Simponi
Product Name: Simponi
Trade Name: Entyvio 300 mg
Product Name: Entyvio 300 mg
Trade Name: XELJANZ
Product Name: XELJANZ

CHU Amiens-Picardie

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

100

Phase 4

France

EUCTR2020-002695-12-NL
(EUCTR)

14/10/2020

02/09/2020

Treatment of refractory pouchitis with tofacitinib

Tofacitinib in the treatment of chronic, recurrent and/or antibiotic refractory pouchitis: a multi-omics approach - TOFA-Pouchitis

Chronic, recurrent and/or antibiotic refractory pouchitis in patients with ulcerative colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Trade Name: Xeljanz 5mg film-coated tablets

Amsterdam UMC, location AMC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Netherlands

NCT04424303
(ClinicalTrials.gov)

September 30, 2020

8/6/2020

Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

Evaluation of the Clinical Benefit of ToFAcitinib Treatment in Patients With Moderate to Severe Ulcerative Colitis Under Real-life Conditions of Use: TOFAst Study

Ulcerative Colitis

Drug: Tofacitinib

Pfizer

NULL

Not yet recruiting

18 Years

N/A

All

280

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04338204
(ClinicalTrials.gov)

September 14, 2020

4/4/2020

Observational Study To Assess The Effectiveness Of Tofacitinib In Ulcerative Colitis In Clinical Practice In Sweden

Observational Study of Tofacitinib in Ulcerative Colitis in Sweden (ODEN)

Ulcerative Colitis

Drug: tofacitinib

Pfizer

NULL

Recruiting

18 Years

99 Years

All

120

Sweden

EUCTR2019-004652-11-SI
(EUCTR)

28/08/2020

31/08/2020

A Study of Etrolizumab-Based Induction Therapy Combinations Followed by Etrolizumab Maintenance Therapy in Patients with Moderate-To-Severe Ulcerative Colitis

RANDOMIZED, OPEN-LABEL PHASE 3B STUDY OF ETROLIZUMAB BASED INDUCTION THERAPY COMBINATIONS FOLLOWED BY ETROLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS - Lantana

Ulcerative Colitis (UC)
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: Etrolizumab
Product Code: RO5490261/F04-02
INN or Proposed INN: Etrolizumab
Other descriptive name: rhuMAb Beta7, Anti Beta7, PRO145223
Trade Name: Remicade
INN or Proposed INN: INFLIXIMAB
Other descriptive name: INFLIXIMAB
Trade Name: Xeljanz
INN or Proposed INN: TOFACITINIB
Other descriptive name: TOFACITINIB
Trade Name: Xeljanz
INN or Proposed INN: TOFACITINIB
Other descriptive name: TOFACITINIB
Trade Name: Stelara
INN or Proposed INN: USTEKINUMAB
Other descriptive name: USTEKINUMAB
Trade Name: Stelara
INN or Proposed INN: USTEKINUMAB
Other descriptive name: USTEKINUMAB

F. Hoffmann-La Roche Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

372

Phase 3

Serbia;United States;Slovakia;Spain;Ukraine;Ireland;Israel;Russian Federation;Italy;Switzerland;France;Latvia;Netherlands;Slovenia;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Canada;Argentina;Brazil;Belgium;Poland;Germany

NCT04576000
(ClinicalTrials.gov)

August 25, 2020

17/9/2020

Identification of Biomarkers of Tofacitinib Therapy in Patients With Ulcerative Colitis

PhaRmacOkinetics and PHarmacodynamic BiomarkErs of TofacItinib Therapy in Patients With Ulcerative Colitis (PROPHETIC)

Ulcerative Colitis

Drug: Tofacitinib

Robarts Clinical Trials Inc.

NULL

Recruiting

18 Years

N/A

All

100

United States;Belgium;Canada;Italy;Netherlands;Spain

EUCTR2019-003780-21-NL
(EUCTR)

04/05/2020

21/02/2020

An investigation of tofacitinib in patients with ulcerative colitis

Pharmacokinetics and Pharmacodynamic Biomarkers of Tofacitinib Therapy in Patients with Ulcerative Colitis (PROPHETIC Study)

Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Trade Name: XELJANZ
Product Name: XELJANZ
INN or Proposed INN: TOFACITINIB

Robarts Clinical Trials

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

100

Phase 4

United States;Canada;Spain;Belgium;Netherlands;Italy

EUCTR2018-004890-28-IT
(EUCTR)

09/10/2019

07/10/2020

Study for the research of predictive factors of response to Tofacitinib therapy in patients with ulcerative rectal colitis.

(A)nalysis of immunological (VA)riables in ex vivo (T)ofacitinib-treated human biopsies from (A)ctive ulcerative colitis patients to predict clinical (R)esponse (the AVATAR study). - AVATAR

Ulcerative colitis
MedDRA version: 20.0;Level: LLT;Classification code 10045282;Term: UC;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Trade Name: Xeljanz
Product Name: Xeljanz
Product Code: [N/A]

DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 4

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03591770
(ClinicalTrials.gov)

July 31, 2019

9/7/2018

Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

Inflammatory Bowel Diseases

Biological: SHINGRIX

Boston Medical Center

NULL

Suspended

50 Years

N/A

All

100

Phase 4

United States

EUCTR2018-004587-61-NL
(EUCTR)

23/04/2019

13/05/2019

Characterization of lipid changes in patients with ulcerative colitis treated with tofactinib or infliximab

Deep profiling of lipid changes in patients with active ulcerative colitis treated with either tofacitinib or infliximab - LIPID

Ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Erasmus Medical Center

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 4

Netherlands

EUCTR2017-002274-39-NL
(EUCTR)

27/06/2018

19/12/2017

A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Ulcerative colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Trade Name: XELJANZ
Product Name: Tofacitinib citrate
Product Code: CP -690,550 -10
INN or Proposed INN: tofacitinib
Other descriptive name: CP -690,550

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3;Phase 4

United States;Serbia;Slovakia;Spain;Ukraine;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Belgium;Poland;South Africa;Netherlands;Germany;Japan;New Zealand;Korea, Republic of

EUCTR2017-002274-39-GB
(EUCTR)

12/04/2018

20/12/2017

A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Ulcerative colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3;Phase 4

Serbia;United States;Slovakia;Spain;Ukraine;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;South Africa;Netherlands;Germany;New Zealand;Japan;Korea, Republic of

EUCTR2017-002274-39-BE
(EUCTR)

22/02/2018

18/12/2017

A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Trade Name: XELJANZ
Product Name: Tofacitinib citrate
Product Code: CP -690,550 -10
INN or Proposed INN: tofacitinib
Other descriptive name: CP -690,550

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3;Phase 4

United States;Poland;Serbia;South Africa;Czechia;Germany;Slovakia;Spain;Ukraine;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Netherlands;Japan;New Zealand;Korea, Republic of;Canada;Belgium

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2017-002274-39-CZ
(EUCTR)

16/01/2018

14/12/2017

A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Trade Name: XELJANZ
Product Name: Tofacitinib citrate
Product Code: CP -690,550 -10
INN or Proposed INN: tofacitinib
Other descriptive name: CP -690,550

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3;Phase 4

EUCTR2017-002274-39-AT
(EUCTR)

04/01/2018

20/12/2017

A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Trade Name: XELJANZ
Product Name: Tofacitinib citrate
Product Code: CP -690,550 -10
INN or Proposed INN: tofacitinib
Other descriptive name: CP -690,550

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

130

Phase 3

EUCTR2017-002274-39-HU
(EUCTR)

21/12/2017

19/12/2017

A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Trade Name: XELJANZ
Product Name: Tofacitinib citrate
Product Code: CP -690,550 -10
INN or Proposed INN: tofacitinib
Other descriptive name: CP -690,550

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3;Phase 4

United States;Serbia;Slovakia;Spain;Ukraine;Austria;Russian Federation;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Belgium;Poland;South Africa;Germany;Netherlands;Japan;New Zealand;Korea, Republic of

EUCTR2017-002274-39-ES
(EUCTR)

21/12/2017

22/12/2017

A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Trade Name: XELJANZ
Product Name: Tofacitinib citrate
Product Code: CP -690,550 -10
INN or Proposed INN: tofacitinib
Other descriptive name: CP -690,550

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3

EUCTR2017-002274-39-SK
(EUCTR)

08/12/2017

27/10/2017

A multi-center parallel group study of tofacitinib in subjects with ulcerative colitis in stable remission

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Trade Name: XELJANZ
Product Name: Tofacitinib citrate
Product Code: CP -690,550 -10
INN or Proposed INN: tofacitinib
Other descriptive name: CP -690,550

Pfizer Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Phase 3;Phase 4

United States;Serbia;Slovakia;Spain;Ukraine;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Belgium;South Africa;Germany;Netherlands;Japan;New Zealand;Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03281304
(ClinicalTrials.gov)

November 16, 2017

11/9/2017

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

A PHASE 3B/4,MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Ulcerative Colitis

Drug: CP -690,500 5 mg;Drug: CP -690,550 10 mg

Pfizer

NULL

Active, not recruiting

18 Years

N/A

All

141

Phase 4

United States;Belgium;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom

EUCTR2016-002691-27-NL
(EUCTR)

19/10/2017

01/06/2017

An open label study to study changes in the structure of the mucosa of the bowel in subjects during treatment with tofacitinib for moderate to severe ulcerative colitis

An open label exploratory analysis of the histological, immunological and microbiome changes of the colonic mucosa during treatment with tofacitinib for moderate-severe ulcerative colitis - TOFA-histo

Ulcerative colitis
MedDRA version: 20.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Trade Name: Xeljanz 5 mg film-coated tablets

Academic Medical Center

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Netherlands

NCT03103412
(ClinicalTrials.gov)

May 4, 2017

24/3/2017

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD-3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

Drug: TD-3504;Drug: 15N2-tofacitinib;Drug: Placebo

Theravance Biopharma

NULL

Completed

18 Years

55 Years

All

Phase 1

United States

EUCTR2011-004579-35-HR
(EUCTR)

27/08/2013

28/08/2014

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Moderate to severe active Ulcerative Colitis
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand

EUCTR2011-004581-14-HR
(EUCTR)

26/08/2013

28/08/2014

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Ulcerative colitis
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

725

Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004580-79-HR
(EUCTR)

26/08/2013

28/08/2014

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

EUCTR2011-004578-27-HR
(EUCTR)

26/08/2013

28/08/2014

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004578-27-NL
(EUCTR)

04/03/2013

12/03/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Ulcerative colitis
MedDRA version: 15.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

Poland;Belgium;Brazil;Romania;Croatia;Germany;Japan;United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada

EUCTR2011-004581-14-IT
(EUCTR)

18/01/2013

07/08/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Ulcerative colitis (UC)
MedDRA version: 14.1;Level: LLT;Classification code 10045282;Term: UC;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 14.1;Level: SOC;Classification code 10017947;Term: Gastrointestinal disorders;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: NA
Product Code: CP -690,550-10
Other descriptive name: tofacitinib
Product Name: NA
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

PFIZER LIMITED

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

725

United States;Estonia;Taiwan;Spain;Ukraine;Austria;Russian Federation;Israel;Colombia;United Kingdom;Italy;India;Hungary;Czech Republic;Canada;Brazil;Denmark;Australia;South Africa;Germany;Netherlands;Latvia;Japan;Korea, Republic of

EUCTR2011-004580-79-IT
(EUCTR)

18/01/2013

07/08/2012

maintenance therapy with CP-690,550 in subjects with ulcerative colitis

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

ulcerative colitis (UC)
MedDRA version: 14.1;Level: LLT;Classification code 10045282;Term: UC;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 14.1;Level: SOC;Classification code 10017947;Term: Gastrointestinal disorders;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: NA
Product Code: CP -690,550-10
Other descriptive name: tofacitinib
Product Name: NA
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

PFIZER LIMITED

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

654

United States;Taiwan;Estonia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;Australia;Denmark;South Africa;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Brazil;Croatia;Germany;New Zealand;Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004578-27-IT
(EUCTR)

18/01/2013

07/08/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Ulverative colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: NA
Product Code: CP -690,550-10
Other descriptive name: tofacitinib
Product Name: NA
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

PFIZER INC.

NULL

Not Recruiting

Female: yes
Male: yes

545

United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Korea, Democratic People's Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Croatia;Germany;Japan

EUCTR2011-004579-35-NL
(EUCTR)

10/10/2012

12/03/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Moderate to severe active Ulcerative Colitis
MedDRA version: 15.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Brazil;Romania;Croatia;Germany;New Zealand

EUCTR2011-004581-14-NL
(EUCTR)

10/10/2012

12/03/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: Tofacitinib citrate (clinical trial image)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib
Product Name: Tofacitinib citrate (Proposed commercial formulation - debossed)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

900

Phase 3

Serbia;United States;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Italy;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Belgium;Poland;Croatia;Romania;Germany;New Zealand

EUCTR2011-004578-27-PL
(EUCTR)

18/09/2012

20/06/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Ulcerative colitis
MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Brazil;Belgium;Poland;Romania;Croatia;Germany;New Zealand;Japan

EUCTR2011-004581-14-PL
(EUCTR)

17/09/2012

22/06/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: Tofacitinib citrate (clinical trial image)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib
Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib

Pfizer Inc., 235 East 42nd Street, New York, New York 10017, United States

NULL

Not Recruiting

Female: yes
Male: yes

900

Phase 3

United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004579-35-PL
(EUCTR)

17/09/2012

28/06/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Moderate to severe active Ulcerative Colitis
MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Brazil;Belgium;Poland;Romania;Croatia;Germany;New Zealand

EUCTR2011-004580-79-PL
(EUCTR)

05/08/2012

12/06/2012

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Ulcerative colitis
MedDRA version: 18.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Brazil;Belgium;Poland;Romania;Croatia;Germany;New Zealand;Japan

EUCTR2011-004578-27-ES
(EUCTR)

11/07/2012

09/03/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Ulcerative colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Belgium;Brazil;Romania;Croatia;Germany;Japan

EUCTR2011-004579-35-ES
(EUCTR)

11/07/2012

09/03/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Moderate to severe active Ulcerative Colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004579-35-CZ
(EUCTR)

29/06/2012

08/02/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Moderate to severe active Ulcerative Colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc

,NULL

Not Recruiting

Female: yes
Male: yes

545

Phase 3

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004581-14-CZ
(EUCTR)

29/06/2012

08/02/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Pfizer Inc.

NULL

Not Recruiting

Female: yes
Male: yes

900

Phase 3

EUCTR2011-004578-27-CZ
(EUCTR)

29/06/2012

08/02/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc

,NULL

Not Recruiting

Female: yes
Male: yes

545

Phase 3

EUCTR2011-004580-79-CZ
(EUCTR)

26/06/2012

08/02/2012

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Ulcerative colitis
MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan;Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy

EUCTR2011-004579-35-BE
(EUCTR)

08/06/2012

08/03/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Moderate to severe active Ulcerative Colitis
MedDRA version: 16.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004580-79-BE
(EUCTR)

08/06/2012

07/03/2012

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004581-14-BE
(EUCTR)

07/06/2012

07/03/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: Tofacitinib citrate (clinical trial image)
Product Code: CP -690,550-10
Other descriptive name: tofacitinib
Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed)
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

900

Phase 3

Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan

EUCTR2011-004578-27-BE
(EUCTR)

06/06/2012

07/03/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004580-79-DE
(EUCTR)

06/06/2012

28/03/2012

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Product Code: CP -690,550-10
INN or Proposed INN: not available
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

Germany;New Zealand;Japan;Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Brazil;Belgium;Romania;Croatia

NCT01458951
(ClinicalTrials.gov)

June 2012

21/10/2011

A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.

Ulcerative Colitis

Drug: tofacitinib;Drug: Placebo

Pfizer

NULL

Completed

18 Years

N/A

All

547

Phase 3

United States;Australia;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Korea, Republic of;Latvia;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom

EUCTR2011-004578-27-HU
(EUCTR)

30/05/2012

10/02/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004579-35-DE
(EUCTR)

29/05/2012

21/03/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
INN or Proposed INN: not available
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA

NULL

Not Recruiting

Female: yes
Male: yes

545

Phase 3

EUCTR2011-004578-27-LV
(EUCTR)

23/05/2012

01/03/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004578-27-DE
(EUCTR)

23/05/2012

05/03/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
INN or Proposed INN: not availble
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA

NULL

Not Recruiting

Female: yes
Male: yes

545

Phase 3

EUCTR2011-004579-35-LV
(EUCTR)

23/05/2012

01/03/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004581-14-LV
(EUCTR)

23/05/2012

01/03/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

725

Phase 3

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004580-79-LV
(EUCTR)

23/05/2012

01/03/2012

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

EUCTR2011-004578-27-AT
(EUCTR)

18/05/2012

27/03/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
INN or Proposed INN: not available
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004580-79-AT
(EUCTR)

18/05/2012

27/03/2012

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Product Code: CP -690,550-10
INN or Proposed INN: not available
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

EUCTR2011-004581-14-ES
(EUCTR)

18/05/2012

14/03/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

725

EUCTR2011-004580-79-ES
(EUCTR)

18/05/2012

09/03/2012

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Belgium;Brazil;Romania;Croatia;Germany;Japan;New Zealand;United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004581-14-AT
(EUCTR)

18/05/2012

27/03/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib
Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

900

Phase 3

United States;Serbia;Estonia;Taiwan;Slovakia;Spain;Ukraine;Israel;Russian Federation;Italy;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;New Zealand

EUCTR2011-004579-35-AT
(EUCTR)

18/05/2012

21/03/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
INN or Proposed INN: not available
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004581-14-HU
(EUCTR)

10/05/2012

10/02/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: Tofacitinib citrate (clinical trial image)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib
Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

900

Phase 3

United States;Serbia;Taiwan;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Colombia;Italy;India;France;Denmark;Australia;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Brazil;Belgium;Poland;Croatia;Romania;Germany;Japan

EUCTR2011-004579-35-HU
(EUCTR)

10/05/2012

10/02/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand

EUCTR2011-004580-79-HU
(EUCTR)

10/05/2012

10/02/2012

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy;India;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Brazil;Belgium;Romania;Croatia;Germany;New Zealand;Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004580-79-SK
(EUCTR)

03/05/2012

10/04/2013

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

EUCTR2011-004579-35-SK
(EUCTR)

02/05/2012

13/04/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004581-14-SK
(EUCTR)

02/05/2012

13/04/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: Tofacitinib citrate (clinical trial image)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib
Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib

Pfizer Inc.

NULL

Not Recruiting

Female: yes
Male: yes

900

Phase 3

EUCTR2011-004578-27-SK
(EUCTR)

02/05/2012

12/04/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004581-14-GB
(EUCTR)

01/05/2012

01/03/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: Tofacitinib citrate (clinical trial image)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib
Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

900

Phase 3

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004579-35-GB
(EUCTR)

01/05/2012

12/01/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004578-27-EE
(EUCTR)

26/04/2012

14/02/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004578-27-GB
(EUCTR)

26/04/2012

12/01/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

EUCTR2011-004581-14-EE
(EUCTR)

26/04/2012

13/02/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: Tofacitinib citrate (clinical trial image)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib
Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

900

Phase 3

EUCTR2011-004579-35-EE
(EUCTR)

26/04/2012

14/02/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004580-79-EE
(EUCTR)

26/04/2012

13/02/2012

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

NCT01465763
(ClinicalTrials.gov)

April 2012

21/10/2011

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

Drug: tofacitinib;Drug: Placebo

Pfizer

NULL

Completed

18 Years

N/A

All

614

Phase 3

United States;Australia;Austria;Belgium;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;Brazil

EUCTR2011-004581-14-DK
(EUCTR)

20/03/2012

09/02/2012

A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: Tofacitinib citrate (clinical trial image)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib
Product Name: Tofacitinib citrate (Proposed commercial formulation – debossed)
Product Code: CP -690,550-10
INN or Proposed INN: tofacitinib
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

900

Phase 3

Serbia;United States;Estonia;Slovakia;Spain;Ukraine;Israel;Russian Federation;Italy;France;Australia;Denmark;South Africa;Latvia;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Belgium;Poland;Croatia;Romania;Germany;New Zealand

EUCTR2011-004580-79-DK
(EUCTR)

24/02/2012

23/01/2012

A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS

Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

654

Phase 3

EUCTR2011-004579-35-DK
(EUCTR)

24/02/2012

A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Moderate to severe active Ulcerative Colitis
MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

Phase 3

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-004578-27-DK
(EUCTR)

24/02/2012

09/02/2012

A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Product Name: CP -690,550-10
Product Code: CP -690,550-10
Other descriptive name: tofacitinib

Pfizer Inc, 235 East 42nd Street, New York, New York 10017

NULL

Not Recruiting

Female: yes
Male: yes

545

Phase 3